Pfizer (PFE) Tops Q2 EPS by 1c, Updates FY EPS Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Pfizer Reports Second-Quarter 2017 Results
August 1, 2017 6:45 AM EDTSecond-Quarter 2017 Revenues of $12.9 Billion, Comparable Operationally with the Prior-Year Quarter; Unfavorably Impacted by $295 Million, or 2%, Due to the February 2017 Divestiture of Hospira Infusion Systems Second-Quarter 2017 Reported Diluted EPS(1) of $0.51, Adjusted Diluted EPS(2) of $0.67 Raised Midpoint of 2017 Adjusted Diluted EPS(2) Guidance Range by $0.02 to a Range of $2.54 to $2.60; Reaffirmed 2017 Revenue Guidance Range of $52.0 to $54.0 Billion
NEW YORK--(BUSINESS WIRE)-- Pfizer Inc. (NYSE: PFE) reported financial results for second-quarter 2017, increased the midpoint of its 2017 financial guidance range for Adjusted diluted EPS(2) and reaffirmed its... More
